‘Dangling’ Accelerated Approval Reviews Expand At US FDA

 
• By Michael McCaughan
US FDA's oncology center is starting to look at a wider array of accelerated approvals as it continues to consider 'dangling' indications. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers